CA-170 (AUPM-170), a PDL1 inhibitor, is primarily used in cancer immunotherapy. It works by blocking the PD-1/PD-L1 pathway, which cancer cells exploit to evade the immune system. By inhibiting this interaction, it enhances the immune system's ability to recognize and attack tumor cells. This makes it a promising candidate for treating various cancers, including non-small cell lung cancer, melanoma, and bladder cancer. Its application is particularly significant in cases where traditional therapies have limited effectiveness, offering a targeted approach to boost the body's natural defenses against cancer.